Lundbeck plans to beat competition with proof of efficient migraine treatment
In spite of new study data documenting quick onset from Lundbeck's migraine treatment Vyepti, the pharmaceutical company does not plan to position the drug as an acute treatment. "That would be the wrong place for it to compete," says Lundbeck Head of Research & Development Johan Luthman, who instead wishes to strengthen the company's position on the main market.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN
On Monday, the major pharmaceutical company Lundbeck received good news in the form of study data underlining the pharmaceutical drug Vyepti's quick-acting effect in patients with chronic migraines – according to the company, this might become an advantage in the battle against competitors on the migraine-treatment market.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
